title: [HDL: the yin-yang of cardiovascular disease].
abstract: Epidemiological studies demonstrate an inverse correlation between plasma HDL-cholesterol (HDL-C) concentration and incidence of cardiovascular disease (CVD). The antiatherogenic role of HDL has been attributed to its anti-inflammatory, antithrombotic and antioxidant properties, besides its participation in the reverse cholesterol transport (RCT), whereby cholesterol from peripheral tissues (including macrophages of the arterial intima) is delivered to the liver for excretion in bile. Due to these actions, HDL-C has evolved as an attractive target for prevention of CVD. However, the failure of torcetrapib, drug that substantially increases HDL-C levels, in preventing CVD and data from studies with animal models and with carriers of monogenic disorders affecting HDL-C levels in humans provide conflicting data about HDL being antiatherogenic. This review addresses the current state of knowledge regarding HDL based on these recent controversies.
authors.affiliation: Laboratório de Lípides, Disciplina de Endocrinologia e Metabologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, SP, Brasil. camilacanteiro@gmail.com
authors.forename: Camila Canteiro
authors.initials: CC
authors.lastname: Leança
authors.forename: Marisa
authors.initials: M
authors.lastname: Passarelli
authors.forename: Edna R
authors.initials: ER
authors.lastname: Nakandakare
authors.forename: Eder C R
authors.initials: EC
authors.lastname: Quintão
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001692:Biological Transport; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D011804:Quinolines / Q000627:therapeutic use*; D016709:Yin-Yang
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D011804:Quinolines; C483909:torcetrapib